Leerink Partnrs Has Optimistic Outlook of LXRX Q4 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities research analysts at Leerink Partnrs boosted their Q4 2024 earnings estimates for shares of Lexicon Pharmaceuticals in a research note issued on Thursday, November 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.09). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.69) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ FY2025 earnings at ($0.50) EPS and FY2026 earnings at ($0.25) EPS.

A number of other equities analysts also recently commented on LXRX. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Trading Down 8.0 %

NASDAQ LXRX opened at $0.98 on Monday. The stock has a market cap of $240.13 million, a P/E ratio of -1.30 and a beta of 1.24. Lexicon Pharmaceuticals has a fifty-two week low of $0.97 and a fifty-two week high of $3.73. The stock has a 50 day simple moving average of $1.61 and a two-hundred day simple moving average of $1.73. The company has a debt-to-equity ratio of 0.56, a quick ratio of 11.49 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. During the same period in the previous year, the business earned ($0.21) earnings per share.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its stake in Lexicon Pharmaceuticals by 82.6% during the first quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 26,859 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock worth $15,363,000 after purchasing an additional 420,854 shares during the last quarter. Boulder Hill Capital Management LP bought a new position in Lexicon Pharmaceuticals in the 1st quarter worth about $615,000. Virtu Financial LLC bought a new position in Lexicon Pharmaceuticals in the 1st quarter worth about $105,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at about $912,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.